Toni K. Choueiri

Toni K. Choueiri, MD is Director of the Lank Center for Genitourinary Oncology and the Jerome and Nancy Kohlberg Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School. He is among the most decorated and prolific oncology researchers of his generation, with a career built on a seamless integration of clinical trial leadership, translational discovery, and international collaboration that has reshaped the treatment of renal cell carcinoma (RCC) and other genitourinary cancers. Dr. Choueiri is the principal architect of the International Metastatic RCC Database Consortium (IMDC) prognostic model, also known as the Heng/IMDC criteria, developed through large-scale multicenter international collaboration. This model refined and expanded upon the MSKCC criteria, incorporating six prognostic factors including hemoglobin, calcium, neutrophils, and platelets, and has become the universally adopted risk stratification tool in all contemporary first-line RCC trials and clinical practice guidelines worldwide. He has also been a lead investigator for multiple landmark phase III trials, including KEYNOTE-426 (pembrolizumab plus axitinib versus sunitinib) and CABOSUN (cabozantinib versus sunitinib in intermediate/poor-risk RCC), establishing practice-changing treatment standards across risk groups. Dr. Choueiri's translational program encompasses the molecular biology of RCC, mechanisms of resistance to VEGF and immune checkpoint blockade, hereditary kidney cancer syndromes, and the development of novel biomarkers. He has authored more than 500 peer-reviewed publications and is among the most highly cited oncology researchers globally. He serves as Chair of the ASCO Genitourinary Cancers Symposium Scientific Program Committee and on multiple NIH and international guideline panels, and has received numerous national and international awards recognizing his transformative contributions to genitourinary oncology.